undamentalytics Newsletter
Sign in

Organon & Co. income statement

In fiscal 2025, Organon & Co. reported revenue of $6.22bn, down 2.9% on the year before and net income of $187m, or $0.72 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue7,7776,5326,3046,1746,2636,4036,2166,099
Cost of revenue2,2742,1192,3822,2942,5152,6882,9032,859
Gross profit5,5034,4133,9223,8803,7483,7153,3133,240
Research and development220210443471528469366357
Selling, general and administrative1,4431,3561,6681,7041,8931,7601,7211,712
Interest expense00258422527520504446
Income before tax3,6962,7521,5291,122673807425503
Income tax390496178205−350−57238290
Net income3,2182,1601,3519171,023864187213
Diluted EPS$12.69$8.52$5.31$3.59$3.99$3.33$0.72$0.80
Diluted shares (average)254m254m254m255m256m259m261m267m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ELAN vs OGNJAZZ vs OGNOGN vs ZTS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Organon & Co.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Organon & Co.